{"id":60970,"date":"2024-02-28T07:18:18","date_gmt":"2024-02-28T07:18:18","guid":{"rendered":"https:\/\/medsname.com\/selgin\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"selgin","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/selgin\/","title":{"rendered":"Selgin"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer<\/h3>\n

Selgin<\/strong> je peror\u00e1ln\u00ed selegiline<\/strong> (5 mg) tablet \u2014 a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> pou\u017e\u00edvan\u00e1 k l\u00e9\u010db\u011b Parkinson disease<\/strong>. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Selegiline is metabolised to L-amphetamine and L-methamphetamine<\/strong>, which can contribute to insomnia — take morning doses only. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. D\u016fle\u017eit\u00e9:<\/strong> avoid combination with most antidepressants (SSRIs, SNRIs, TCAs), opioids such as pethidine and tramadol, and dextromethorphan — risk of serotoninov\u00fd syndrom<\/em>.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

What Is Selgin?<\/h2>\n

Selgin is an oral tablet containing selegiline 5 mg<\/strong>. selegiline is a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> originally introduced as Eldepryl \/ Jumex<\/strong>. Selgin is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n

Selegiline was the first MAO-B inhibitor used in Parkinson disease, in clinical use since the 1980s. It can be used as monotherapy<\/em> in early Parkinson disease (modest symptomatic benefit, may delay the need for levodopa by months) or as adjunct<\/em> to levodopa to reduce “wearing-off” between doses. Its distinctive feature among MAO-B inhibitors is that it is metabolised to amphetamine derivatives, which contribute to a mild stimulant effect — useful for fatigue but a frequent cause of insomnia.<\/p>\n

How Does Selgin (selegiline) Work?<\/h2>\n

In the brain, dopamine is degraded mainly by monoamine oxidase type B (MAO-B). Selegiline irreversibly inactivates MAO-B at standard doses (5–10 mg\/day), so dopamine released from surviving neurones lingers longer in the synapse. The result: smoother symptom control and a longer benefit from each levodopa dose. Selegiline is also metabolised to L-amphetamine and L-methamphetamine, which independently contribute mild stimulant and dopaminergic effects. Above 10 mg\/day, selectivity for MAO-B is lost and MAO-A inhibition becomes clinically meaningful — tyramine restriction then becomes important.<\/p>\n

Comparing the MAO-B Inhibitors<\/h2>\n

The three MAO-B inhibitors used in Parkinson disease — selegiline, rasagiline and safinamide — share a common mechanism but differ meaningfully in metabolites, dosing and clinical positioning:<\/p>\n\n\n\n\n\n\n\n\n\n
Vlastnost<\/th>\nSelegiline<\/th>\nRasagiline<\/th>\nSafinamide<\/th>\n<\/tr>\n<\/thead>\n
Typical dose<\/td>\n5–10 mg\/day<\/td>\n0.5–1 mg\/day<\/td>\n50–100 mg\/day<\/td>\n<\/tr>\n
Active metabolites<\/td>\nAmphetamine + methamphetamine<\/td>\nAminoindan (non-amphetamine)<\/td>\nNo active stimulant metabolite<\/td>\n<\/tr>\n
Glutamate effect<\/td>\nNe<\/td>\nNe<\/td>\nAno<\/strong> — sodium-channel\/glutamate-release modulation<\/td>\n<\/tr>\n
Indikace<\/td>\nMonotherapy or adjunct<\/td>\nMonotherapy or adjunct<\/td>\nAdjunct only<\/strong> — for fluctuating PD on levodopa<\/td>\n<\/tr>\n
Insomnia risk<\/td>\nHigher (amphetamine metabolites)<\/td>\nLow<\/td>\nLow<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Who Is Selgin For?<\/h2>\n

Selgin is appropriate for adults with Parkinson disease — either as initial monotherapy in early disease (when symptoms are mild and the patient is reluctant to start levodopa) or as adjunct to levodopa in patients with end-of-dose “wearing-off”. Older patients prone to insomnia may tolerate rasagiline or safinamide better. Not appropriate during current SSRI\/SNRI\/TCA therapy or for patients planning to take pethidine, tramadol or other contraindicated medications.<\/p>\n

Dosing and Administration<\/h2>\n

The standard adult dose is 5 mg once daily with breakfast<\/strong>, increased to 5 mg twice daily (breakfast and lunch) after 1–2 weeks<\/strong> if needed for symptom control. Avoid evening doses<\/em> — the amphetamine metabolites cause insomnia. Maximum 10 mg\/day at standard MAO-B selectivity. Doses up to 20–30 mg\/day have been used historically but cross into non-selective MAO inhibition with full tyramine-diet implications.<\/p>\n\n\n\n\n\n\n\n
F\u00e1ze<\/th>\nD\u00e1vka<\/th>\nTiming<\/th>\n<\/tr>\n<\/thead>\n
Week 1–2 (initiation)<\/td>\n5 mg once daily<\/td>\nWith breakfast<\/td>\n<\/tr>\n
Udr\u017eovac\u00ed d\u00e1vka<\/td>\n5 mg dvakr\u00e1t denn\u011b<\/td>\nBreakfast and lunch — never evening<\/td>\n<\/tr>\n
Maximum at MAO-B selectivity<\/td>\n10 mg\/day<\/td>\nBeyond this, tyramine restriction needed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
⚠ Tyramine and the “cheese effect”<\/strong> At standard MAO-B-selective doses, dietary tyramine restriction is generally ne<\/em> required. However, MAO-B selectivity is dose-dependent — selegiline above 10 mg\/day, rasagiline above 1 mg\/day, and safinamide above 100 mg\/day lose selectivity and inhibit peripheral MAO-A as well. At those doses, tyramine-rich foods (aged cheeses, cured meats, broad beans, fermented soya, draught beer) can trigger a hypertensive crisis. Stay within prescribed doses to avoid this risk.<\/div>\n

B\u011b\u017en\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n

Insomnia (very common — the most common reason for discontinuation), headache, nausea, dizziness, postural hypotension, dry mouth, increased liver enzymes. Less common: confusion, hallucinations, agitation, mood changes. With levodopa: increased dyskinesia, may need to lower the levodopa dose by 10–30%.<\/p>\n

⚠ Serotonin syndrome — dangerous interactions<\/strong> Combining a MAO-B inhibitor with serotonergic drugs can cause serotoninov\u00fd syndrom<\/em>: agitation, sweating, tremor, hyperreflexia, fever, diarrhoea, in severe cases seizures and death. Avoid:<\/strong> SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram), SNRIs (venlafaxine, duloxetine), tricyclics (amitriptyline, imipramine), pethidine (meperidine), tramadol, dextromethorphan, methadone, St John’s wort, MDMA. Wash-out periods:<\/strong> stop fluoxetine 5 weeks before starting MAO-B inhibitor; stop other SSRIs\/SNRIs at least 2 weeks before; do not start fluoxetine within 2 weeks of stopping the MAO-B inhibitor.<\/div>\n

Drug and Food Interactions<\/h2>\n